Member Info for daveycaferacer

the valuation is ridiculous, but I think this is brought on by the further news about potential Chinese firms with U.S. listing being de-listed, or having to comply with tough disclosure and accounting rules (which Hutchmed does anyway).

amazing, the share price is now back where it was 4 years ago........

More fantastic clinical progress today with the completion of patient enrollment of FRESCO-2. Outside of China Fruquintinib has forecast annual peak sales of $1.2bn in refractory CRC so this is a very valuable asset.

Nice news today that SULANDA® (surufatinib) has been included in the NRDL and ELUNATE® (fruquintinib) will continue to be on the list. However, I'm puzzled about ORPATHYS® (savolitinib) as the updates states " It was also included in the 2021 negotiations with the NHSA, however HUTCHMED and AstraZeneca, its partner on ORPATHYS®, declined inclusion in the NRDL for 2022." Does that mean Hutchmed and AZ declined or were declined by the NHSA... A moot point given the niche target patient population for Exon14 but it would be interesting to know.

I do not understand the share price, it can be up 2-3% in HK and on the same day drop 5% on NASDAQ, the reverse can then happen the following day. It seems there could be some form of arbitrage trading going on.

hahaha I wish saigon! and yes I think you are right jatw, M&A, let's hope we are not the A unless they wish to pay a rather large premium!

Yes, I agree, and I cannot understamnd how the Court permitted the company to do a capital reduction and move what was effectively an asset with some tradeable value (eg. Accustem made up a proportion of Tiziana's market capitalisation prior to the so-called demerger), to a Company where the asset effectively has no value. It may have value in the future but as it stands right now Tiziana shareholders have been compensated with an IOU note, with an open ended redemption date.

I wonder of there is some arbitrage trading going on - it's down a few percent in HK, then up in the UK and also in the U.S. pre-market. There's little correlation and a lot of lag between the markets.

On another note I notice Beigene is listing on the STAR market, something that Hutchmed may also consider.

to add, at least it's only Options to buy and nothing more committed!

very interesting observation jatw....

Someone was buying big yesterday in Hong Kong but plenty of selling on NASDAQ today. The stock price never seems to sustain any rise. I am hopeful however that the FDA approval of Surufatinib in the next few months will be a major catalyst. I also hope that a continued significant increase in revenue and positive cashflow by 2025/6 will put our valuation in the tens of billions.

There is little information and data on clinical trial progress, and nothing about how they intend to push the assets into registration trials. Most companies would publish very detailed results but te presentations are light on detail and light on the Company's strategy, which suggests they may not have one.

There is a DB Investor conference today @ 13:00 and a Jefferies London h/c summit session tomorrow

All the details are on the website

a new article has been posted at Oncolive

https://www.onclive.com/view/surufatinib-toripalimab-combo-elicits-encouraging-efficacy-in-advanced-neuroendocrine-carcinoma

https://twitter.com/hutchmed/status/1459058667370647553?s=20

I hope the Board of Directors are ashamed of the way they have treated Shareholders and of the way they've scammed people with the worthless capital reduction.

I hope the Board of Directors are ashamed of the way they have treated Shareholders and of the way they've scammed people with the worthless capital reduction.

I do wonder how the UK court can agree the divestment and capital reduction without cast iron assurances that shareholders will be compensated. The Company said Accustem would be listed, the court accepted that as sufficient, but Accustem has not been listed and there is no guarantee that it will.

The share price is approx 20% lower than it was 4 years ago and seems to defy all logic to me. Much larger, deeper, late stage pipeline, 3 drugs on the market compared to zero in late 2018, the first drug outside China to have approval very soon and yet we are back to October 2017 levels. I simply cannot understand the market. Whilst the Company's valuation may have been a little over-extended back then the current valuation seems to have priced in failure, despite the Company's excellent track record of success and execution.

Patients including my daughters need the best, most accurate prognosis test on the market. The Company needs to get it onto the market quickly for the sake of patients and investors and they need to work out the best way to do it. There's no pint in having the best assay test if it's not accessible to anyone.

indeed Jatw, but I am always bemused at Beigene's valuation on a ttm basis - currently at a p/s of 34 against HCM's 15
Future growth seems to be baked in to Beigene far more than it does Hutchmed suggesting the upside for Hutchmed is considerable. If the Company delivers on 5 therapies launched outside China and 109 in China by 2025 the valuation must surely be many multiples of today. I have no doubt they will achieve these objectives given the fantastic track record so far.